Z01 BC 010020 (Z01) | |||
---|---|---|---|
Title | Clinical Trials with Immunotoxins | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Pastan, Ira | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $769,963 | Project Dates | 10/01/1995 - N/A |
Fiscal Year | 2008 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Childhood Cancers (5.0%) Digestive Diseases (5.0%) Hematology (80.0%) Neurosciences Research (5.0%) |
Brain (5.0%) Childhood Leukemia (5.0%) Leukemia (5.0%) Lung (20.0%) Lymphoma (8.0%) Non Hodgkins Lymphoma (8.0%) Ovarian Cancer (10.0%) Pancreas (5.0%) Prostate (5.0%) |
||
Research Type | |||
Vaccines Systemic Therapies - Clinical Applications |
|||
Abstract | |||
<p>Phase 1 trials with HA22, a new more active form of BL22 have been initiated in HCL and acute lymphoblastic leukemia.</p><p>A phase 2 trial with immunotoxin BL22 that targets CD22 on Hairy Cell Leukemia has been completed. 32 patients have been treated and about half of these patients have under gone complete remissions.</p><p>A phase 1 trial with HA22 in pediatric acute lymphocytec leukemia is open in collaboration with Dr. Alan Wayne, P.O.B.</p><p>Two phase 1 trials with immunotoxin SS1P given by continuous infusion or Q.O.D. x 3 for mesothelioma, pancreatic cancer and ovarian cancer have been completed. Several minor responses were observed. A phase 2 trial combining SS1P with chemotherapy has opened recently.</p><p>Phase 1 trials in CLL and CTCL with immunotoxin LMB 2 targeting CD25 are open. A phase 1 trial treating brain tumors with immunotoxin MRI- 1FvPE38 has just opened at Duke in collaboration with Darrel Bigner.</p><p>A Phase 1 trial treating patients with mesothelioma with monoclonal antibody (MORAB-009) has been completed.</p> |